2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy …
M Packer - Circulation, 2022 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …
on the evolution and progression of cardiomyopathy and nephropathy, which is …
Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effects of SGLT2 inhibitors on kidney and cardiovascular function
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …
SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
[HTML][HTML] Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi… - … England Journal of …, 2019 - Mass Medical Soc
Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction
Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …
[PDF][PDF] SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in …
M Packer - Diabetes Care, 2020 - sochob.cl
RY rheostat, whereas AMPK discerns the balance between ATP and AMP in the cytosol.
Importantly, SIRT1 and AMPK are activated not only by fasting but also by a broad range of …
Importantly, SIRT1 and AMPK are activated not only by fasting but also by a broad range of …
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
DZI Cherney, CCJ Dekkers, SJ Barbour… - The lancet Diabetes & …, 2020 - thelancet.com
Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …
Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) …
M Packer - Circulation: Heart Failure, 2020 - Am Heart Assoc
The cardioprotective effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors may be
related to their ability to induce a fasting-like paradigm, which triggers the activation of …
related to their ability to induce a fasting-like paradigm, which triggers the activation of …